Cross-reactive bactericidal antimeningococcal antibodies can be isolated from convalescing invasive meningococcal disease patients using reverse vaccinology 2.0
The threat from invasive meningococcal disease (IMD) remains a serious source of concern despite the licensure and availability of vaccines. A limitation of current serogroup B vaccines is the breadth of coverage afforded, resulting from the capacity for extensive variation of the meningococcus and...
| Príomhchruthaitheoirí: | , , , , |
|---|---|
| Formáid: | Journal article |
| Foilsithe / Cruthaithe: |
Frontiers Research Foundation
2018
|